Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.66 |
| ▸ | HTR3B | O95264 | 1/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | HTR3A | P46098 | 1/20 | 0.66 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.66 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20748280 | 1.00 | HTR3E (0.66) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL20415005 | 1.00 | HTR3E (0.66) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL20415006 | 1.00 | HTR3E (0.66) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL2925759 | 0.98 | HTR3E (0.68) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL28599511 | 0.89 | HTR3E (0.73) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL29656856 | 0.89 | HTR3E (0.73) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL18409051 | 0.87 | HTR3E (0.56) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL9658356 | 0.87 | HTR3E (0.56) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL10769390 | 0.87 | HTR3E (0.56) | HTR3EHTR3BADRB1HTR3AHTR3D | |
| SCHEMBL31164294 | 0.86 | MAPT (0.68) | MAPTRAB9AKMT2AALDH1A1NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102239146-A | Novel compounds as calcium channel blockers | ABBOTT LAB | 2011-11-09 | — | — | CN | claimed |
| CN-111315828-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-09-29 | — | — | CN | disclosed |
| CN-112154167-B | Composition, cured product, optical filter, and method for producing cured product | 株式会社艾迪科 | 2023-08-22 | — | — | CN | disclosed |
| US-RE49582-E1 | Therapeutic compounds and compositions | AGIOS PHARMACEUTICALS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11656548-B2 | Actinic ray-sensitive or radiation-sensitive resin composition, resist film, pattern forming method, mask blank with resist film, method for producing photomask, and method for manufacturing electronic device | FUJIFILM CORPORATION (JP) | 2023-05-23 | — | — | US | disclosed |
| CN-111848412-B | Method for efficiently realizing N-alkylation reaction by using cycloiridium catalyst | 赣南医学院 | 2023-05-12 | — | — | CN | disclosed |
| CN-112341376-B | Preparation method of cycloolefine amine sulfone derivative | 温州医科大学 | 2022-12-06 | — | — | CN | disclosed |
| US-11112693-B2 | Curable coloring composition, color filter, solid-state imaging device, image display device, and method for producing cured film | FUJIFILM CORPORATION (JP) | 2021-09-07 | — | — | US | disclosed |
| WO-2021096496-A1 | METHODS FOR FORMING ARYL CARBON-NITROGEN BONDS USING LIGHT AND PHOTOREACTORS USEFUL FOR CONDUCTING SUCH REACTIONS | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2021-05-20 | — | — | WO | disclosed |
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | G1 THERAPEUTICS, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20020042534-A1 | Method for producing an alpha-aminonitrile from a tertiary anime and a cyanide through oxidation with oxygen by using a transition metal catalyst | OSAKA UNIVERSITY (JP) | 2002-04-11 | — | — | US | disclosed |
| WO-2002006245-A1 | SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF | SYNAPTIC PHARMARCEUTICAL CORPORATION (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-1174419-A1 | A method for producing an alpha-aminonitrile from a tertiary amine and a cyanide through oxidation with oxygen by using a transition metal catalyst | OSAKA UNIVERSITY (JP) | 2002-01-23 | — | — | EP | disclosed |
| WO-2002002744-A2 | DNA ENCODING A HUMAN MELANIN CONCENTRATING HORMONE RECEPTOR (MCH1) AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-2002000574-A2 | CATALYSIS USING PHOSPHINE OXIDE AND SULFOXIDE COMPOUNDS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-01-03 | — | — | WO | disclosed |
| US-6291722-B1 | CONTACTING GRIGNARD REAGENT OF FORMULA R.SUP.7--MGX WITH AN ARYL COMPOUND OF THE FORMULA R.SUP.1--X IN THE PRESENCE OF A CATALYTIC AMOUNT OF COORDINATION COMPRISING TRASITION METAL COMPLEXED TO PHOSPHINE OXIDE TO PREPARE BISARYL COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-09-18 | — | — | US | disclosed |
| WO-2001040147-A1 | CATALYSIS USING PHOSPHINE OXIDE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
| US-6124462-A | PREPARING ARYLAMINE AND BIARYLS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2000-09-26 | — | — | US | disclosed |
| EP-0836599-A1 | 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002259-A1 | 1,6-DISUBSTITUTED ISOCHROMANS FOR TREATMENT OF MIGRAINE HEADACHES | PHARMACIA & UPJOHN COMPANY (US) | 1997-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981887-B2 | Benzothiophene estrogen receptor modulators | ESR1, GPER1, ESR2 | HTR3E 407/4885HTR3B 609/4885ADRB1 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.